COFCO Capital Holdings Co., Ltd. (002423.SZ)
CNY 12.68
(0.96%)
CNY 12.68
(0.96%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 9.06 Billion CNY | -19.61% |
| 2022 | 11.27 Billion CNY | 112.96% |
| 2021 | 5.29 Billion CNY | 120.86% |
| 2020 | 2.39 Billion CNY | 794.87% |
| 2019 | 267.88 Million CNY | -77.68% |
| 2018 | 1.2 Billion CNY | 61.42% |
| 2017 | 743.59 Million CNY | 85.9% |
| 2016 | 400 Million CNY | -17.53% |
| 2015 | 485 Million CNY | 35.1% |
| 2014 | 359 Million CNY | -10.25% |
| 2013 | 400 Million CNY | 300.0% |
| 2012 | 100 Million CNY | 0.0% |
| 2011 | 100 Million CNY | 0.0% |
| 2010 | 100 Million CNY | 0.0% |
| 2009 | 100 Million CNY | 0.0% |
| 2008 | 100 Million CNY | 0.0% |
| 2007 | - CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 6.97 Billion CNY | -23.05% |
| 2024 Q2 | 10.94 Billion CNY | 56.93% |
| 2024 Q3 | 9.9 Billion CNY | -7.12% |
| 2023 Q2 | 13.61 Billion CNY | -8.35% |
| 2023 Q3 | 11.29 Billion CNY | -17.06% |
| 2023 FY | 9.06 Billion CNY | -19.61% |
| 2023 Q4 | 9.06 Billion CNY | -19.74% |
| 2023 Q1 | 14.85 Billion CNY | 31.77% |
| 2022 Q3 | 11.89 Billion CNY | -11.03% |
| 2022 FY | 11.27 Billion CNY | 112.96% |
| 2022 Q4 | 11.27 Billion CNY | -5.22% |
| 2022 Q2 | 13.37 Billion CNY | 0.45% |
| 2022 Q1 | 13.31 Billion CNY | 61.28% |
| 2021 FY | 5.29 Billion CNY | 120.86% |
| 2021 Q3 | 9.63 Billion CNY | 22.1% |
| 2021 Q1 | 7.95 Billion CNY | 232.02% |
| 2021 Q4 | 8.25 Billion CNY | -14.37% |
| 2021 Q2 | 7.89 Billion CNY | -0.82% |
| 2020 Q2 | 4.16 Billion CNY | 43.37% |
| 2020 Q4 | 2.39 Billion CNY | -25.48% |
| 2020 FY | 2.39 Billion CNY | 794.87% |
| 2020 Q1 | 2.9 Billion CNY | 985.56% |
| 2020 Q3 | 3.21 Billion CNY | -22.84% |
| 2019 FY | 267.88 Million CNY | -77.68% |
| 2019 Q3 | 2.12 Billion CNY | 14.74% |
| 2019 Q4 | 267.88 Million CNY | -87.37% |
| 2019 Q2 | 1.84 Billion CNY | -31.32% |
| 2019 Q1 | 2.69 Billion CNY | 152.52% |
| 2018 Q4 | 1.06 Billion CNY | -5.41% |
| 2018 Q1 | 540.01 Million CNY | 11.8% |
| 2018 FY | 1.2 Billion CNY | 61.42% |
| 2018 Q3 | 1.12 Billion CNY | -4.85% |
| 2018 Q2 | 1.18 Billion CNY | 119.37% |
| 2017 Q2 | 392 Million CNY | -1.06% |
| 2017 Q3 | 485.4 Million CNY | 23.83% |
| 2017 Q4 | 483 Million CNY | -0.49% |
| 2017 Q1 | 396.2 Million CNY | -0.95% |
| 2017 FY | 743.59 Million CNY | 85.9% |
| 2016 Q4 | 400 Million CNY | -11.11% |
| 2016 FY | 400 Million CNY | -17.53% |
| 2016 Q2 | 470 Million CNY | -13.76% |
| 2016 Q3 | 450 Million CNY | -4.26% |
| 2016 Q1 | 545 Million CNY | 12.37% |
| 2015 Q2 | 255 Million CNY | -28.97% |
| 2015 FY | 485 Million CNY | 35.1% |
| 2015 Q4 | 485 Million CNY | 40.58% |
| 2015 Q3 | 345 Million CNY | 35.29% |
| 2015 Q1 | 359 Million CNY | 0.0% |
| 2014 Q2 | 500 Million CNY | 8.7% |
| 2014 Q4 | 359 Million CNY | -34.06% |
| 2014 FY | 359 Million CNY | -10.25% |
| 2014 Q1 | 460 Million CNY | 15.0% |
| 2014 Q3 | 544.42 Million CNY | 8.88% |
| 2013 Q2 | 100 Million CNY | 0.0% |
| 2013 Q1 | 100 Million CNY | 0.0% |
| 2013 Q4 | 400 Million CNY | 3.63% |
| 2013 FY | 400 Million CNY | 300.0% |
| 2013 Q3 | 386 Million CNY | 286.0% |
| 2012 Q1 | 100 Million CNY | 0.0% |
| 2012 Q2 | 70 Million CNY | -30.0% |
| 2012 Q3 | 60 Million CNY | -14.29% |
| 2012 Q4 | 100 Million CNY | 66.67% |
| 2012 FY | 100 Million CNY | 0.0% |
| 2011 Q1 | 100 Million CNY | 0.0% |
| 2011 FY | 100 Million CNY | 0.0% |
| 2011 Q4 | 100 Million CNY | 19.05% |
| 2011 Q3 | 84 Million CNY | -16.0% |
| 2011 Q2 | 100 Million CNY | 0.0% |
| 2010 FY | 100 Million CNY | 0.0% |
| 2010 Q1 | 100 Million CNY | 0.0% |
| 2010 Q3 | 5 Million CNY | -95.0% |
| 2010 Q4 | 100 Million CNY | 1900.0% |
| 2010 Q2 | 100 Million CNY | 0.0% |
| 2009 Q4 | 100 Million CNY | 0.0% |
| 2009 FY | 100 Million CNY | 0.0% |
| 2008 FY | 100 Million CNY | 0.0% |
| 2007 FY | - CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Hubei Biocause Pharmaceutical Co., Ltd. | 25.41 Billion CNY | 64.339% |